Investigational drug · Phase 2
HCW9218
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Pancreatic Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "HCW9218"
First trial start
2022
Oct 17, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HCW9218", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Pancreatic Carcinoma
Approved drugs for the same conditions: Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "HCW9218" as an intervention, largest first.
ImmunityBio, Inc.Industry
NCT05304936 · 21 participants · Start Oct 17, 2022 · Primary completion Feb 15, 2025
Drug: HCW9218; Gemcitabine (GEM) and 1 more · For: Advanced Pancreatic Carcinoma
Sites: Scottsdale, Arizona; Bethesda, Maryland; St Louis, Missouri · 5 sites in all
Masonic Cancer Center, University of MinnesotaAcademic, hospital or other
NCT05322408 · 18 participants · Start Apr 1, 2022 · Primary completion Jan 2, 2025
Drug: HCW9218 · For: Solid Tumor
Sites: Minneapolis, Minnesota
Haider MahdiAcademic, hospital or other
NCT05145569 · 0 participants · Start May 10, 2024 · Primary completion May 31, 2026
Drug: Carboplatin AUC 5 and paclitaxel; HCW9218 · For: Ovarian Cancer
Newest research
PubMed records naming it or its code names, newest first.
- Natural Killer Cell TGF-β Signaling Regulates Postnatal Lung Development.
Gainer DJ, Coyle KM, Rätsep MT, et al. · Circ Res 2026
- Enhancing HIV-1-specific CAR-T cell functional activity by treatment with a novel cytokine-based scaffold with IL-15 superagonist and TGF-β-neutralizing activity.
Lamcaj S, Cole E, Hiner C, et al. · J Virol 2026
- TGF-βRII/IL-15 immunotherapeutic complex targets exhausted CD8+ T-cell subsets in lymph nodes and tumors.
George VK, Wong HC, Felices M, et al. · J Immunother Cancer 2025
- Development of analytical methods for detection of anti-drug antibodies neutralizing IL-15 and TGF-β RII activity.
Leclerc GM, Egan JO, You L, et al. · J Immunoassay Immunochem 2025
- Immunotherapeutic approach to reduce senescent cells and alleviate senescence-associated secretory phenotype in mice.
Shrestha N, Chaturvedi P, Zhu X, et al. · Aging Cell 2023
- Immunotherapeutic HCW9218 augments anti-tumor activity of chemotherapy via NK cell-mediated reduction of therapy-induced senescent cells.
Chaturvedi P, George V, Shrestha N, et al. · Mol Ther 2022
Also in development for Advanced Pancreatic Carcinoma
- GEMPhase 35 trials
Shenzhen Majory Biotechnology Co., Ltd. · Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.